In yesterday’s Wall Street session, Zomedica Corp (AMEX:ZOM) shares traded at $0.16, down -2.92% from the previous session.
1 analysts cover Zomedica Corp (AMEX:ZOM), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $0.44 and a low of $0.44, we find $0.44. Given the previous closing price of $0.16, this indicates a potential upside of 175.0 percent. ZOM stock price is now -11.13% away from the 50-day moving average and -25.93% away from the 200-day moving average. The market capitalization of the company currently stands at $152.87M.
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $0.44 as their price target over the next twelve months.
With the price target of $6, Dawson James recently initiated with Buy rating for Zomedica Corp (AMEX: ZOM).
In other news, HEATON LARRY C II, CEO bought 100,000 shares of the company’s stock on May 26. The stock was bought for $19,090 at an average price of $0.19. Upon completion of the transaction, the CEO now directly owns 100,000 shares in the company, valued at $16000.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 25, Director POWERS JOHNNY D bought 100,000 shares of the business’s stock. A total of $19,340 was incurred on buying the stock at an average price of $0.19. This leaves the insider owning 1,600,000 shares of the company worth $0.26 million. A total of 1.44% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ZOM stock. A new stake in Zomedica Corp shares was purchased by SQUAREPOINT OPS LLC during the first quarter worth $50,000. XTX TOPCO LTD invested $32,000 in shares of ZOM during the first quarter. In the first quarter, CITADEL ADVISORS LLC acquired a new stake in Zomedica Corp valued at approximately $12,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in ZOM for approximately $9,000. NORTHROCK PARTNERS, LLC purchased a new stake in ZOM valued at around $2,000 in the second quarter. In total, there are 94 active investors with 8.76% ownership of the company’s stock.
On Wednesday morning Zomedica Corp (AMEX: ZOM) stock kicked off with the opening price of $0.1600. During the past 12 months, Zomedica Corp has had a low of $0.15 and a high of $0.34. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 19.37, and a quick ratio of 18.86. The fifty day moving average price for ZOM is $0.1748 and a two-hundred day moving average price translates $0.2102 for the stock.
The latest earnings results from Zomedica Corp (AMEX: ZOM) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0, inline with analysts’ expectations of $0. This compares to -$0.01 EPS in the same period last year. The net profit margin was -86.64% and return on equity was -7.40% for ZOM. The company reported revenue of $6.02 million for the quarter, compared to $4.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 41.78 percent. For the current quarter, analysts expect ZOM to generate $8.28M in revenue.
Zomedica Corp(ZOM) Company Profile
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
